End Of An Era As Generic Versions Of BMS’s Controversial Blockbuster Revlimid Arrive
Gradual Decline From $12bn Peak Expected
Executive Summary
Revlimid was the driving force behind Celgene’s growth, but also became symbolic in the ongoing row over US drug prices.
You may also be interested in...
All Eyes On Bristol's New Launches
Bristol Myers Squibb has launched three new first-in-class drugs this year – Opdualag, Camzyos and Sotyktu – and investors are closely watching the early momentum.
Dr Reddy’s Debuts Two Revlimid Exclusives As Part Of Complete Launch In US
Dr Reddy’s Laboratories is set to reap the rewards of a significant US generic launch – albeit one with a limited volume caveat decreed by a patent-litigation settlement deal – after it began selling its generic of Bristol Myers Squibb’s multi-billion-dollar blockbuster Revlimid.
BMS Gets First Immunotherapy Approval In Neoadjuvant Lung Cancer, Quickly
Opdivo gets approved by the US FDA for neoadjuvant non-small cell lung cancer, an important new early-stage indication for the anti-PD-1 agent that cleared the agency in roughly two months.